Jeffrey Marc Leiden
Executive ChairmanDr. Jeffrey Marc Leiden, M.D., Ph.D., serves as an Executive Chairman at Vertex Pharmaceuticals Incorporated since April 2020. He joined the Vertex Pharmaceuticals Incorporated in July 2009. At the Vertex Pharmaceuticals Incorporated, he also served as Chairman since May 2012, as Chief Executive Officer and President from February 1, 2012 to March 31, 2020 and as lead independent director from October 2010 to December 2011. During his tenure, Dr. Leiden led the Vertex Pharmaceuticals Incorporated as it discovered and developed four medicines that treat the underlying cause of Cystic Fibrosis as well as a gene editing treatment for Sickle Cell Disease and Thalassemia. He serves as Lead Director at Massachusetts Mutual Life Insurance Company since 2024 and as a Director since February 10, 2015. Dr. Leiden is Non-Executive Chairman at Tmunity Therapeutics, Inc. since January 2021 and Chairman of the Board at Casana Care, Inc. He serves as an Independent Chairman of the Board at Odyssey Therapeutics, Inc. since March 2022, where he also served as its Executive Chairman. Additionally, he serves as Chairman of the Perelman School of Medicine at the University of Pennsylvania, Co-Chairman of Massachusetts Governor Deval Patrick's Science, Technology, Engineering and Math (STEM) Advisory Council and Chair of the Scientific Advisory Board of Brigham and Women's Hospital. His advisory roles include serving as a Member of the Strategic Advisory Board at Osmind Inc since 2024, Member of the Advisory Council at BrightInsight, Inc. since March 2021, Strategic Advisor of J.P. Morgan Life Sciences Private Capital, Co-Chairman of the Advisory Council for Harvard Immunology, Member of the MIT CEO Advisory Board and Member of the Scientific Advisory Board of Boston Children's Hospital. He is a Director of the Massachusetts Competitive Partnership and the Boston Private Industry Council, a Trustee of the Brigham and Women's Hospital, a Member of the Board of Trustees at Ravinia Festival Association, a Trustee of the Museum of Science and Industry, a Trustee of the Keystone Symposia and a member of the Harvard Medical School Board of Fellows. Previously, Dr. Leiden was Independent Chairman of the Board and a Director at Revolution Healthcare Acquisition Corp. from April 2021 to December 2022. He served as a Director of Quest Diagnostics Incorporated from December 1, 2014 to May 15, 2019. He was Managing Director of Clarus Ventures (also known as Blackstone Life Sciences) from 2006 to January 2012 and also served as a senior advisor. From 2006 to January 2012, he was a Director and the non-executive Vice Chairman of the board of Shire plc. At Abbott Laboratories, he served as the President and Chief Operating Officer of the Pharmaceutical Products Group from 2001 to 2006, Executive Vice President of Pharmaceuticals and Chief Scientific Officer from 2000 to 2001 and a Director from 1999 to March 2006. He was also a Director of TAP Pharmaceutical Products Inc from 2001 to 2006. From July 1999 to July 2000, he was an Elkan R. Blout Professor of Biological Sciences at Harvard School of Public Health and Professor of Medicine at Harvard Medical School. At the University of Chicago, he served as the Chief of Cardiology and Director of the Cardiovascular Research Institute from 1987 to 2000 and as the Frederick H. Rawson Professor of Medicine and Pathology from 1992 to July 1999. From 1987 to 1992, he was an Attending Physician and Assistant Investigator of the Howard Hughes Medical Institute at the University of Michigan. He is Founder of Vical Incorporated and Co-Founder of Cardiogene Therapeutics Inc. His prior board roles include Chairman of Variation Biotechnologies Inc., Chairman of VBI Vaccines, Chairman and Director of Lycera Corp., Chairman and Director of TYRX, Inc. from February 2008, Director of Biolex Therapeutics, Inc. from October 2008, Director of Catabasis Pharmaceuticals, Independent Director of Millennium Pharmaceuticals, Inc. from October 4, 2007 and Member of the Scientific Advisory Board at Massachusetts Life Sciences Center until September 30, 2011. Dr. Leiden is an elected fellow of the American Academy of Arts and Sciences and a Member of the Institute of Medicine of the National Academy of Sciences. He has published more than 130 peer reviewed papers. His honors include a Lifetime Achievement in Biopharma by Forbes in 2020, being named one of Forbes' America's Most Innovative Leaders in 2019, a Power 50 Honoree by the Boston Business Journal and one of the 100 Most Influential People in Boston by Boston Magazine. He earned a B.A. in Biological Sciences, an M.D. and a Ph.D. with honors in Virology from the University of Chicago. He has also received an honorary M.A. from Harvard University.
Positions
- Company NameVertex Pharmaceuticals IncorporatedStock CodeVRTXPositionExecutive ChairmanColleagues
- JMJeffrey Marc LeidenExecutive Chairman
- RKReshma KewalramaniCEO, President & Director
- CFCharles F. WagnerExecutive VP, COO & CFO
- AKAmit K. SachdevExecutive VP & Chief Patient and External Affairs Officer
- OTOurania TatsisExecutive VP & Chief Product Affairs Officer
- BIBruce I. SachsLead Independent Director
- LALloyd A. CarneyIndependent Director
- MLMichel LagardeIndependent Director
- Company NameOdyssey Therapeutics, Inc.Stock CodeODTXPositionIndependent Chairman of the BoardColleagues
- GDGary D. GlickFounder, President, CEO & Director
- JHJason HaasChief Financial Officer
- CTCollin ToddSenior Vice President of Strategy & Business Development
- ELEicke LatzScientific Co-Founder
- KLKim LewisScientific Co-Founder
- SCStephen C. BlacklowChairman of Scientific Advisory Board
- IFIan F. SmithIndependent Director
- VOValerie OdegardIndependent Director
